XVIVO Perfusion – Consensus estimates Q4 2025
2026-01-22 14:00:00
Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.
Number of contributors: 6 (all of which have been updated or confirmed before the report)
| KPI (MSEK, unless otherwise specified) | Q4 2025E |
| Net sales | 214 |
| Organic growth in local currency (%) | 2.70 |
| Gross profit | 160 |
| EBITDA | 43.2 |
| EBIT | 25.5 |
| Net profit | 19.1 |
| Earnings per share (SEK) | 0.60 |
XVIVO Perfusion’s Q4 report will be released on Tuesday 27 January at 07.30 CET.